Monograph Details
|
|
Eye Disorders
> Ocular allergy/inflammation
|
|
XIBROM |
| Manufacturer |
|
ISTA Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
NSAID. |
| Generic Name |
|
Bromfenac 0.09%, oph soln; contains benzalkonium chloride, sulfites. |
| Indications |
|
Post-operative inflammation and pain following cataract extraction. |
| Children |
<18yrs: not recommended.
|
| Adults |
|
≥18yrs: 1 drop in affected eye(s) twice daily starting 24 hours post-op for 2 weeks. |
| Precautions |
|
Bleeding tendencies. May delay wound healing. Complicated/repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Contact lenses (remove during therapy). Risk of corneal adverse events may be increased if used more than 24hrs before surgery, or beyond 14-days post-op. Pregnancy (Cat.C; avoid during 3rd trimester). Nursing mothers. |
| Interactions |
|
May potentiate oral anticoagulants, others that prolong bleeding. |
| Adverse Reactions |
|
Ocular effects (eg, conjunctival hyperemia, burning, stinging, pain, pruritus, redness, iritis), headache. |
| How Supplied |
|
Soln—5mL |
|
|
|
|
